Orphan Drug Designation

Orphan drug designation is a special regulatory status granted by the U.S. Food and Drug Administration to promote the development of treatments for rare diseases affecting fewer than 200,000 patients nationwide. This designation provides benefits such as tax credits, market exclusivity, and fee waivers to encourage pharmaceutical companies to invest in therapies that might otherwise be commercially unviable. It plays a critical role in advancing medical innovation for underserved patient populations.



Orphan Drug Designation Recent News